First-line treatment of patients with metastatic pancreatic cancer: results of a Phase II trial with S-1 (CESAR-Study group).
Strumberg
D
D
Department of Hematology and Oncology, University of Bochum, Marienhospital Herne, Herne, Germany. dirk.strumberg@marienhospital-herne.de
Bergmann
L
L
Graeven
U
U
Hanauske
A
A
Lipp
R
R
Schuette
J
J
Schultheis
B
B
Scigalla
P
P
Urrea
P
P
Scheulen
M E
ME
D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D004338:Drug Combinations; D006801:Humans; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D005641:Tegafur / Q000009:adverse effects / Q000627:therapeutic use*
D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid